Belite Bio announced additional positive secondary endpoint data from its Phase 3 DRAGON trial for tinlarebant, a drug treating Stargardt disease type 1 (STGD1). The data showed a significant divergence in toxic bisretinoid accumulation between the treatment and placebo groups, reinforcing the drug's efficacy and contributing to a 3% stock gain.
Belite Bio released new secondary endpoint statistics from its Phase 3 DRAGON trial for tinlarebant, targeting Stargardt disease type 1 (STGD1). The key finding was a notable divergence in quantitative autofluorescence (qAF), a marker for toxic bisretinoid accumulation, between the treatment and placebo groups. Patients receiving tinlarebant showed stable or slightly decreased qAF, while the placebo group experienced a 20% escalation. This positive data, building on previously met primary endpoints, suggests strong efficacy for a drug addressing an unmet medical need. This is a significant positive for BLTE, as it de-risks the drug's development and potential market approval, leading to a short-term stock price increase and long-term opportunity for the company in the rare disease space.